LAZR vs SGMO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SGMO Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sangamo Therapeutics, Inc. Common Stock (SGMO) driven by superior Valuation, Growth & Margin, Options & Structure while LAZR counters with relative strength in Momentum & Technical. Fundamentally, LAZR trades at N/M Forward P/E with -340.9% operating margin (+21.0% YoY revenue) versus SGMO at 0.4x Forward P/E and -175.5% operating margin (+88.4% YoY). In options structure, LAZR sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LAZR | SGMO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $14.7M | $55.9M | Larger Scale | SGMO |
| Trailing P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | SGMO |
| Forward P/E Ratio Valuation | N/M | 0.4x | Lower Multiple | SGMO |
| Revenue Growth (YoY) Growth | +21.0% | +88.4% | Higher Growth | SGMO |
| Operating Margin (TTM) Profitability | -340.9% | -175.5% | Higher Margin | SGMO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -2424.7% | -2891.8% | Higher ROE | LAZR |
| 52-Week Range Position Momentum | 53% ($0โ$51) | 9% ($0โ$1) | Stronger Trend | LAZR |
| Beta / 30D Volatility Risk Regime | 3.66ฮฒ ยท 99% Vol | 1.49ฮฒ ยท 206% Vol | Lower Realized Risk | LAZR |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 52.0 / 100 (HOLD) | Higher Composite | SGMO |